Merovan Iv (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final step of peptidoglycan cross‑linking. This weakens the wall, leading to osmotic rupture and bacterial cell death, providing broad‑spectrum activity against many Gram‑negative, Gram‑positive and anaerobic pathogens.

The dose of Merovan Iv is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local susceptibility patterns. No fixed regimen is provided here; the prescriber tailors therapy to each individual case.

Safety data for meropenem in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To order Merovan Iv, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Merovan Iv (meropenem) offers a broader spectrum against many resistant Gram‑negative organisms compared with imipenem‑cilastatin, and it is less likely to cause seizures than ertapenem at standard doses. Choice among carbapenems depends on local resistance patterns, infection site, and patient‑specific factors.

Merovan Iv must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Before use, allow the vial to reach room temperature if required, and inspect for particulate matter or discoloration.

Merovan Iv is given as an intravenous infusion, typically diluted in compatible IV fluids and administered over 15‑30 minutes. The infusion rate and duration are set by the prescriber based on the infection severity, patient condition, and renal function.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, seizures (especially in patients with CNS disorders or high plasma concentrations), and renal impairment. Prompt recognition and management of these events are essential.

Merovan Iv should be avoided in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for patients with a history of seizures, severe renal dysfunction, or those receiving interacting medications listed under major interactions.